Is Indegene a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Indegene Ltd is a good quality company .

Is Indegene undervalued or overvalued?

The key valuation ratios of Indegene Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Indegene share price return in the past 10 years?

Data is not available for this company

Is Indegene a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Indegene Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Indegene Ltd - Stock Valuation and Financial Performance

Name: Indegene
Brand: Indegene

BSE: 544172 | NSE: INDGN | Pharmaceuticals & Drugs | Small Cap

Place order

Indegene Share Price

₹640.35 5.00 0.79%
as on 21-Nov'24 16:00

10 Year X-Ray of Indegene:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	31.8%	43.7%	33.3%	8.9%	14.8%	29.7%	68.5%	41.1%	35.2%	30.9%	-
Value Creation Index ⓘ	1.4	2.2	1.5	-0.3	0.1	1.2	4.1	2.0	1.5	1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	234	344	472	475	553	643	966	1,665	2,306	2,590	2,590
Sales YoY Gr.	-	47.2%	37.3%	0.7%	16.5%	16.2%	50.3%	72.3%	38.5%	12.3%	-
Adj EPS ⓘ	0.9	1.7	2	0.2	0.5	4.3	9.1	8.2	10.8	11.7	14.1
YoY Gr.	-	97.7%	17.1%	-92.5%	253.3%	713.2%	110.7%	-9.9%	31.5%	8.7%	-
BVPS (₹) ⓘ	-1.2	0.6	2.6	2.8	3.6	-5.6	16.2	34.3	47.2	63	98.6
Adj Net Profit ⓘ	16.7	33.1	39.1	3	10.6	85.1	179	181	238	260	337
Cash Flow from Ops. ⓘ	12.8	28.8	27.5	23.6	64.6	22.4	172	297	130	508	-
Debt/CF from Ops. ⓘ	2.1	0.5	2.8	3.2	1.1	20.1	0.1	0.1	3	0.8	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	30.7%	36.2%	38.9%	12.3%
Adj EPS ⓘ	33.7%	85.7%	8.8%	8.7%
BVPSⓘ	NA	77.7%	57.1%	33.3%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	30.3	45.6	35.3	2.2	7.3	357.5	163.1	33.2	26.1	20.9	17.4
Op. Profit Mgn % ⓘ	12.7	15.3	14.9	6.1	7.6	22.3	23.9	17.2	17.2	19.5	19.3
Net Profit Mgn % ⓘ	7.2	9.6	8.3	0.6	1.9	12.2	18.6	10.7	10.3	10	13
Debt to Equity ⓘ	0.5	0.2	0.6	0.6	0.5	-4.1	0.1	0	0.4	0.3	0
Working Cap Days ⓘ	0	140	133	154	127	123	110	92	101	114	135
Cash Conv. Cycle ⓘ	0	37	27	42	32	35	59	62	70	73	98

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 38.90%

Return on Equity has declined versus last 3 years average to 17.40%

Net Profit has been subdued in last 3 years 8.82%

Sales growth is not so good in last 4 quarters at 6.46%

Latest Financials - Indegene Ltd.

	Standalone	Consolidated
TTM EPS (₹)	5.8	14.1
TTM Sales (₹ Cr.)	1,046	2,590
BVPS (₹.) ⓘ	74.1	98.6
Reserves (₹ Cr.) ⓘ	1,726	2,312
P/BV ⓘ	8.57	6.44
PE ⓘ	110.24	45.15

From the Market
52 Week Low / High (₹)	468.90 / 736.60
All Time Low / High (₹)	468.90 / 736.60
Market Cap (₹ Cr.)	15,202
Equity (₹ Cr.)	47.9
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Indegene:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Indegene

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Indegene

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	234	344	472	475	553	643	966	1,665	2,306	2,590
Operating Expenses ⓘ	204	291	402	447	511	499	736	1,378	1,910	2,084
Manufacturing Costs	56	44	47	41	62	70	119	214	201	168
Material Costs	0	0	0	0	0	0	0	0	0	0
Employee Cost	104	183	268	317	367	370	536	1,014	1,465	1,652
Other Costs ⓘ	45	64	87	89	82	60	81	149	245	265
Operating Profit ⓘ	30	52	70	28	42	144	231	287	396	505
Operating Profit Margin (%)	12.7%	15.3%	14.9%	5.9%	7.6%	22.3%	23.9%	17.2%	17.2%	19.5%
Other Income ⓘ	4	3	1	3	7	4	31	26	58	76
Interest ⓘ	2	2	10	8	6	9	7	6	31	49
Depreciation ⓘ	7	15	19	12	17	19	26	33	60	76
Exceptional Items ⓘ	0	0	0	0	0	-44	3	-47	0	2
Profit Before Tax ⓘ	24	38	42	11	26	75	231	226	363	459
Tax ⓘ	5	3	3	7	12	26	46	64	97	122
Profit After Tax	18	35	39	4	14	49	186	163	266	337
PAT Margin (%)	7.8%	10.3%	8.3%	0.8%	2.5%	7.7%	19.2%	9.8%	11.5%	13.0%
Adjusted EPS (₹)	0.9	1.8	2.0	0.2	0.7	-0.3	7.6	7.5	12.0	15.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	54	89	130	134	149	-109	320	758	1,046	1,398
Share Capital ⓘ	79	79	79	79	79	0	0	0	44	44
Reserves ⓘ	-24	10	51	55	70	-110	320	758	1,002	1,353
Minority Interest	0	0	0	0	0	89	9	0	0	0
Debt	25	11	66	37	53	435	18	11	394	343
Long Term Debt	2	2	23	1	8	341	18	11	394	333
Short Term Debt	23	9	42	36	45	95	0	0	0	10
Trade Payables	9	31	47	38	47	55	50	74	73	118
Others Liabilities ⓘ	82	59	68	99	78	92	163	441	623	616
Total Liabilities ⓘ	170	190	310	308	326	562	559	1,284	2,137	2,475
Fixed Assets
Gross Block	55	75	141	148	194	219	191	271	863	995
Accumulated Depreciation	26	41	60	74	90	128	105	134	199	258
Net Fixed Assetsⓘ	29	33	81	75	104	92	86	138	664	737
CWIP ⓘ	4	4	9	24	0	28	0	0	0	0
Investmentsⓘ	0	0	1	0	0	13	0	120	614	797
Inventories	0	0	0	0	0	0	0	0	0	0
Trade Receivables	52	73	105	111	90	175	285	444	642	648
Cash Equivalents	16	10	18	9	37	180	140	517	86	191
Others Assetsⓘ	70	69	96	88	95	73	48	66	131	102
Total Assets ⓘ	170	190	310	308	326	562	559	1,284	2,137	2,475

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	13	29	27	24	65	22	172	297	130	508
PBT ⓘ	24	38	42	11	26	75	196	226	363	459
Adjustment ⓘ	10	16	29	23	21	33	17	87	91	78
Changes in Working Capital ⓘ	-15	-18	-26	-3	35	-59	9	54	-216	96
Tax Paid ⓘ	-6	-8	-18	-7	-18	-27	-50	-70	-108	-125
Cash Flow From Investing Activity ⓘ	-6	-17	-77	-21	-19	-19	-24	-160	-893	-327
Capex	-6	-17	-20	-21	-17	-6	-21	-25	-19	-11
Net Investments	0	2	-56	0	0	0	0	-119	-489	-157
Others ⓘ	0	-2	0	0	-2	-12	-4	-16	-386	-160
Cash Flow From Financing Activityⓘ	0	-18	57	-12	-21	136	-132	233	333	-66
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	263	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	-7	383	-61
Interest Paid ⓘ	-2	-2	-9	-8	-6	-4	-4	-3	-18	-32
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	2	-16	65	-4	-15	140	-128	-20	-33	26
Net Cash Flow ⓘ	7	-6	7	-9	25	140	16	370	-430	114

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	0	0	126.12	7.55	22.54	N/A	176.32	30.2	29.5	27.56
ROCE (%)	31.75	43.74	33.32	8.93	14.82	N/A	68.54	41.09	35.2	30.88
Asset Turnover Ratio	1.37	1.91	1.89	1.54	1.75	1.45	1.72	1.81	1.35	1.12
PAT to CFO Conversion(x)	0.72	0.83	0.69	6	4.64	0.45	0.92	1.82	0.49	1.51
Working Capital Days
Receivable Days	81	66	69	83	67	75	87	80	86	91
Inventory Days	0	0	0	0	0	0	0	0	0	0
Payable Days	0	0	0	0	0	0	0	0	0	0

Indegene Ltd Stock News

Indegene Ltd FAQs

What is the share price of Indegene?

Company share prices are keep on changing according to the market conditions. The closing price of Indegene on 21-Nov-2024 16:00 is ₹640.4.

What is the market cap of Indegene?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:00 the market cap of Indegene stood at ₹15,202.

What is the P/E ratio of Indegene?

The latest P/E ratio of Indegene as of 21-Nov-2024 16:00 is 110.2.

What is the P/B ratio of Indegene?

The latest P/B ratio of Indegene as of 21-Nov-2024 16:00 is 8.57.

What is the 52-week high and low of Indegene?

The 52-week high of Indegene is ₹736.6 and the 52-week low is ₹468.9.

What is the TTM revenue of Indegene?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Indegene is ₹1,046 ( Cr.) .

About Indegene Ltd

The company was incorporated as ‘Indegene Lifesystems Private Limited’ at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of the company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by its Shareholders at the EGM held on February 29, 2016 the name of the company was changed to ‘Indegene Private Limited’ and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of the company was changed to better reflect the nature of business undertaken by the company. Thereafter, the registered office of the company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, the company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by its Shareholders at the EGM held on November 7, 2022 and the name of the company was changed to ‘Indegene Limited’ and a fresh certificate of incorporation was issued to the company by the RoC, on November 17, 2022.

The company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for purpose technology. Its portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. Positioned at the intersection of healthcare and technology, the company’s solutions span across different stages of the commercialization lifecycle of drugs and medical devices. Its Enterprise Commercial Solutions and its Omnichannel Activation solutions cater to the commercial functions of life sciences companies while its Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions.

Business area of the company

The company’s Enterprise Commercial Solutions primarily involve assisting life sciences companies with their digital marketing operations. Service providers in this segment assist life sciences companies by creating customized marketing plans and campaigns, expanding their reach to healthcare professionals (HCPs), and providing insights on HCP preferences. Besides, its Omnichannel Activation solutions help life sciences companies leverage a ‘digital first’ approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Here, it plays the role that has traditionally been played by medical representatives who promote products to HCPs through face-to-face interactions. However, using digital technologies and proprietary analytics, it seeks to achieve the same outcome at higher efficiencies and reduced costs. The channels it uses include emails, virtual sales representatives, social media and other digital platforms.

Under its Enterprise Medical Solutions, the company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for its clients. CoEs comprise multidisciplinary teams that work on one or more client engagements. Through these CoEs, it assist with: (i) writing medical content, regulatory submissions, product labels and other medical information; (ii) reviewing medical communications to ensure compliance with regulatory guidelines and ethical practices; (iii) pharmacovigilance services, i.e., the monitoring and processing of adverse occurrences arising from the use of biopharmaceutical products; and (iv) conducting real-world evidence (RWE) based medical research to support market access and pricing strategies. In addition, it offers Enterprise Clinical Solutions and consultancy services. Its Enterprise Clinical Solutions help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. These solutions include digitally enabled patient recruitment for clinical trials, clinical data management and assistance with regulatory submissions.

Key Awards, accreditations and recognition

2016: Ranked 88th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2016: Received the Business World HR Excellence Award for ‘Best Implementation of HR Technology’.
2017: Ranked 86th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2017: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2017: Recognised as one of the ‘Healthy Workplaces in India’ by Arogya World.
2018: Ranked 60th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2018: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2019: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2019: Recognised as one of the ‘Platinum Healthy Workplaces in India’ by Arogya World India Trust.
2020: Ranked in the ‘Top 50’ category of ‘India’s Best Workplaces for Women’ by Great Place to Work, India.
2020: Ranked 96th among ‘India’s Best Companies to Work for’ by Great Place to Work, India.
2020: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2020: Recognised as one of ‘India’s Best Workplaces in Health and Wellness’ by Great Place to Work, India.
2021: Ranked 100th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2021: Ranked in the ‘Top 100’ category of ‘India’s Best Workplaces for Women’ (large organisations) by Great Place to Work, India.
2021: Recognised as one of the ‘100 Best Companies for Women in India’ by Seramount (formerly Working Mother Media) and Avtar Group.
2021: Recognised as one of ‘India’s Best Workplaces in Health and Wellness’ by Great Place to Work, India.
2022: Ranked 438th among ‘Asia-Pacific High-Growth Companies’ by Financial Times.
2022: Recognised as a leader by Everest Group, in its ‘Life Sciences Commercial Services Specialists PEAK Matrix Assessment 2022’.
2022: Recognised for its ‘Commitment to being a Great Place to Work’ by Great Place to Work, India.
2022: Recognised as ‘India’s Best Workplaces in Health and Wellness’ by Great Place to Work, India.
2023: Recognised as one of ‘India’s Best Workplaces in Professional Services’ by Great Place to Work, India.
2023: Awarded under the ‘Data Engineering for Good’ category at the Data Engineering Awards, 2023 by Analytics India Magazine.
2023: Awarded the ‘Best Overall AI-based Analytics Solution’ at the AI Breakthrough Awards, 2023.
2023: Recognised as a life sciences specialist with deep domain pockets and outcomes to match by HFS Horizons in the Life Sciences Service Providers, 2023.
2023: Awarded the Platinum level by Arogya World at the Healthy Workplace Conference and Awards, 2023.
2023: Certified as a great workplace by Great Place to Work Institute, India.
2024: Recognised as a leader by Everest Group, in its ‘Life Sciences Digital Services Specialists PEAK Matrix Assessment 2024’.
2024: Certified as a great workplace by Great Place to Work Institute, India.

Major events and milestones

2005: Raised funding from Nadathur Holdings & Investments Private Limited.
2005: Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.
2005: Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore.
2006: Acquisition of Medsn, Inc. a company in the USA which is engaged in medical education and marketing business, by one of its Material Subsidiaries, Indegene, Inc. through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.
2007: Expanded the company’s services to include European territory 2008.
2008: Received BS ISO/IEC 27001:2005 certification for information security management system.
2009: Received ISO 9001:2000 certification for quality management system.
2012: Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.
2017: Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of its Material Subsidiaries, ILSL Holdings, Inc.
2020: Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of its Material Subsidiaries, ILSL Holdings, Inc.
2020: Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences.
2021: Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC.
2021: Raised equity funding from CA Dawn Investments and Brighton Park Capital.
2021: Received BS ISO/IEC 27701:2019 certification for privacy information management system.
2022: Acquisition of Medical Marketing Economics, LLC by one of its Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.
2022: Expanded global operations with new offices in Mexico.
2023: Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of its Material Subsidiaries, ILSL Holdings, Inc.
2023: Expanded its presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by its subsidiary, Indegene Ireland Limited.
2023: Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform.
2024: Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of its Subsidiaries, Indegene Ireland Limited.
2024: Ranked 167 in The Next 500 India’s Largest Emerging Companies by Fortune India.